Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.59 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.59 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.59 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.59 |
| ▸ | BCHE | P06276 | 2/20 | 0.52 |
| ▸ | ACHE | P22303 | 2/20 | 0.52 |
| ▸ | DRD2 | P14416 | 5/20 | 0.51 |
| ▸ | DRD4 | P21917 | 2/20 | 0.51 |
| ▸ | DRD3 | P35462 | 3/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18047171 | 1.00 | HDAC8 (0.59) | HDAC8HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL18046988 | 0.89 | FAAH (0.52) | HDAC8HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL18046990 | 0.89 | FAAH (0.52) | HDAC8HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL18046240 | 0.86 | HDAC1 (0.46) | HDAC8HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL18046245 | 0.86 | HDAC1 (0.46) | HDAC8HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL18046916 | 0.86 | F2R (0.55) | HDAC8HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL18046918 | 0.86 | F2R (0.55) | HDAC8HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL18046328 | 0.86 | GPR183 (0.57) | HDAC8HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL18046326 | 0.86 | GPR183 (0.57) | HDAC8HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL29607928 | 0.86 | GPR183 (0.57) | HDAC8HDAC3HDAC1HDAC2HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11919839-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | VALO HEALTH, INC. (US) | 2024-03-05 | — | — | US | claimed |
| US-20220073452-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | VALO HEALTH, INC. | 2022-03-10 | — | — | US | claimed |
| EP-3932914-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | Valo Health, Inc. (US) | 2022-01-05 | — | — | EP | claimed |
| US-20180044282-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | VALO EARLY DISCOVERY, INC. | 2018-02-15 | — | — | US | claimed |
| EP-3268358-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | Forma Therapeutics, Inc. (US) | 2018-01-17 | — | — | EP | claimed |
| US-9745253-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2017-08-29 | — | — | US | claimed |
| WO-2016149099-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-09-22 | — | — | WO | claimed |
| US-20160264518-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | Valo Health, LLC | 2016-09-15 | — | — | US | claimed |
| US-11919839-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | VALO HEALTH, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-20220073452-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | VALO HEALTH, INC. | 2022-03-10 | — | — | US | disclosed |
| EP-3932914-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | Valo Health, Inc. (US) | 2022-01-05 | — | — | EP | disclosed |
| US-10988441-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200331847-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | VALO HEALTH, INC. | 2020-10-22 | — | — | US | disclosed |
| US-10508077-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-12-17 | — | — | US | disclosed |
| US-20180297939-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | Valo Health, LLC | 2018-10-18 | — | — | US | disclosed |
| US-20180044282-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | VALO EARLY DISCOVERY, INC. | 2018-02-15 | — | — | US | disclosed |
| EP-3268358-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | Forma Therapeutics, Inc. (US) | 2018-01-17 | — | — | EP | disclosed |
| US-9745253-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| WO-2016149099-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-09-22 | — | — | WO | disclosed |
| US-20160264518-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | Valo Health, LLC | 2016-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044282-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | HDAC8, HDAC7, HDAC1 | HDAC8 1/4885HDAC3 9/4885HDAC1 3/4885 |
| US-20220073452-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | HDAC8, HDAC7, HDAC1 | HDAC8 1/4885HDAC3 9/4885HDAC1 3/4885 |
| US-20200331847-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | HDAC8, HDAC7, HDAC1 | HDAC8 1/4885HDAC3 9/4885HDAC1 3/4885 |
| US-10988441-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | HDAC8, HDAC7, HDAC1 | HDAC8 1/4885HDAC3 9/4885HDAC1 3/4885 |
| US-20160264518-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | HDAC8, HDAC7, HDAC1 | HDAC8 1/4885HDAC3 9/4885HDAC1 3/4885 |
| US-10508077-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | HDAC8, HDAC7, HDAC1 | HDAC8 1/4885HDAC3 9/4885HDAC1 3/4885 |
| US-11919839-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | HDAC8, HDAC7, HDAC1 | HDAC8 1/4885HDAC3 9/4885HDAC1 3/4885 |
| US-20180297939-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | HDAC8, HDAC7, HDAC1 | HDAC8 1/4885HDAC3 9/4885HDAC1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.